Neurocrine Biosciences Inc banner

Neurocrine Biosciences Inc
F:NB3

Watchlist Manager
Neurocrine Biosciences Inc Logo
Neurocrine Biosciences Inc
F:NB3
Watchlist
Price: 148.6 EUR -0.7%
Market Cap: €15B

Wall St Price Targets

NB3 Price Targets Summary
Neurocrine Biosciences Inc

Wall Street analysts forecast NB3 stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NB3 is 141.75 EUR with a low forecast of 105.14 EUR and a high forecast of 186.74 EUR.

Lowest Forecast
Price Target
105.14 EUR
29% Downside
Average Forecast
Price Target
141.75 EUR
5% Downside
Highest Forecast
Price Target
186.74 EUR
26% Upside
Neurocrine Biosciences Inc Competitors:
Price Targets
ANY
ANY Biztonsagi Nyomda Nyrt
9% Upside
MDLZ
Mondelez International Inc
11% Upside
AYTU
Aytu Biopharma Inc
349% Upside
VYNE
Vyne Therapeutics Inc
166% Upside

Revenue
Forecast

36% / Year
Past Growth
13% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss
36% / Year
Past Growth
13% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Over the last 13 years, the compound annual growth rate for Revenue has been 36%. The projected CAGR for the next 8 years is 13%.

Gross Profit
Forecast

N/A
Past Growth
13% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss
N/A
Past Growth
13% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss

The compound annual growth rate for Gross Profit over the next 8 years is 13%.

Operating Income
Forecast

53% / Year
Past Growth
26% / Year
Estimated Growth
Estimates Accuracy
0%
Average Miss
53% / Year
Past Growth
26% / Year
Estimated Growth
Estimates Accuracy
0%
Average Miss

Over the last 13 years, the compound annual growth rate for Operating Income has been 53%. The projected CAGR for the next 8 years is 26%.

Pre-Tax Income
Forecast

46% / Year
Past Growth
38% / Year
Estimated Growth
Estimates Accuracy
-5%
Average Miss
46% / Year
Past Growth
38% / Year
Estimated Growth
Estimates Accuracy
-5%
Average Miss

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 46%. The projected CAGR for the next 3 years is 38%.

Net Income
Forecast

42% / Year
Past Growth
30% / Year
Estimated Growth
Estimates Accuracy
-4%
Average Miss
42% / Year
Past Growth
30% / Year
Estimated Growth
Estimates Accuracy
-4%
Average Miss

Over the last 13 years, the compound annual growth rate for Net Income has been 42%. The projected CAGR for the next 8 years is 30%.

Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is NB3's stock price target?
Price Target
141.75 EUR

According to Wall Street analysts, the average 1-year price target for NB3 is 141.75 EUR with a low forecast of 105.14 EUR and a high forecast of 186.74 EUR.

What is the Revenue forecast for Neurocrine Biosciences Inc?
Projected CAGR
13%

Over the last 13 years, the compound annual growth rate for Revenue has been 36%. The projected CAGR for the next 8 years is 13%.

What is the Gross Profit forecast for Neurocrine Biosciences Inc?
Projected CAGR
13%

The compound annual growth rate for Gross Profit over the next 8 years is 13%.

What is the Operating Income forecast for Neurocrine Biosciences Inc?
Projected CAGR
26%

Over the last 13 years, the compound annual growth rate for Operating Income has been 53%. The projected CAGR for the next 8 years is 26%.

What is the Pre-Tax Income forecast for Neurocrine Biosciences Inc?
Projected CAGR
38%

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 46%. The projected CAGR for the next 3 years is 38%.

What is the Net Income forecast for Neurocrine Biosciences Inc?
Projected CAGR
30%

Over the last 13 years, the compound annual growth rate for Net Income has been 42%. The projected CAGR for the next 8 years is 30%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett